-
Fostering new opportunities in the Greater Bay Area and Asia’s Pharmaceutical Industry
SHANGHAI, July 20, 2026 /PRNewswire/ — Following the landmark success of CPHI & PMEC China in June 2026, which welcomed an unprecedented gathering of industry professionals and fostered pivotal connections across the pharmaceutical supply chain, attention now shifts to South China. Building on this momentum, CPHI & PMEC Shenzhen 2026 will take place from 16-18…
-
GNI Group Completes Acquisition of AYUMI Pharmaceutical
TOKYO, July 01, 2026 (GLOBE NEWSWIRE) — GNI Group Ltd. (TSE: 2160, “GNI Group” or the “Company”) today announced that it has completed the acquisition of all shares of Ayumi Pharmaceutical Holdings Co., Ltd. from shareholders led by Blackstone. As a result, Ayumi Pharmaceutical Holdings Co., Ltd. and its subsidiary, Ayumi Pharmaceutical Co., Ltd. (“Ayumi…
-
TraceLink Named Fortress Cybersecurity Awards Finalist for Enabling the Transformation to a Secure, Auditable Agentic Supply Chain Operating Model
OPUS Platform and OPUS Agents recognized for enabling no-code AI agents to operate as permissioned, traceable participants in regulated pharmaceutical supply chain operations Summary TraceLink has been named a finalist in the 2026 Fortress Cybersecurity Awards for OPUS and OPUS Agents. The recognition highlights TraceLink’s ability to support agentic supply chain operations in one of…
-
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for the combination arm vs 28% for the control arm at week 24. Post-hoc analysis from the phase 3 SENTRY trial suggests SVR35 may predict overall survival (OS); new data from the…
-
Not Just Pharmacy: How Medkart is Building India's Smartest Generic Medicine App
Ahmedabad, Gujarat, India India’s pharmaceutical landscape is undergoing a vital transformation. Despite being home to one of the world’s largest medicine markets, millions of Indian families continue to struggle with the high cost of treatment. Studies show that over 50% of healthcare expenses in India are still paid out-of-pocket, leaving many to either delay care…
-
GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas June 07, 2026 19:41 ET | Source: GNI Group Co., Ltd. TOKYO, June 07, 2026 (GLOBE NEWSWIRE) — GNI Group Co., Ltd. (TSE: 2160) today announced that it has entered into an agreement to acquire 100% of the shares…
-
LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 June 07, 2026 19:30 ET | Source: LENZ Therapeutics, Inc. SAN DIEGO, June 07, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ, “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine…
-
Havih, a Maxwell Biosciences Subsidiary, Announces Partnership with the Government of Andhra Pradesh
This partnership will establish a new research and production facility in Andhra Pradesh, driving India’s transition toward pharmaceutical leadership and creating high-tech jobs Pulivendula, Andhra Pradesh, India Havih Envirosciences, an Indian citizen-owned and operated life sciences company and subsidiary of Maxwell Biosciences, announced a strategic partnership with the Government of Andhra Pradesh to establish advanced…
-
Raay Neo Pharma Launches to Transform India's Healthcare Landscape with Quality-Driven, Patient-Centric Pharmaceutical Solutions
Mumbai, Maharashtra, India Raay Neo Pharma, a next-generation pharmaceutical company, has officially unveiled its operations with the aim to contribute to quality healthcare for all Indians. Founded using a flexible and scalable operational framework and supported by more than five decades of diverse entrepreneurial success, Raay Neo Pharma will be introducing its range of more…
-
Servier to Acquire Edgewise Therapeutics’ Muscular Dystrophy Business
Acquisition supports Servier’s strategic ambition in rare neurology for patients with high unmet medical needs. Transaction includes sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. Transaction represents total value of up to $2.65 billion. SURESNES, France, June 1, 2026 /PRNewswire/ — Servier, an independent international pharmaceutical group governed by a foundation, today announced that…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.